Current medical research and opinion
-
Randomized Controlled Trial Multicenter Study
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
Determine the efficacy and tolerability of oxymorphone extended release (OPANA ER) in opioid-naive patients with moderate to severe chronic low back pain (CLBP). ⋯ Stabilized doses of oxymorphone ER were generally safe and effective over a 12-week double-blind treatment period in opioid-naive patients with CLBP.
-
Meta Analysis
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Debilitating pain, occurring in 50-70% of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain. ⋯ This review was based on a small number of trials and patients. Pain related to MS was assumed to be similar to neuropathic pain.
-
Randomized Controlled Trial
Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
This decision-analytic study was intended to determine the expected cost-effectiveness of linezolid compared to vancomycin for treating surgical site infections (SSIs) caused by methicillin-resistant Staphyloccocus aureus (MRSA) from the perspective of a tertiary-care academic medical center. ⋯ Using decision-analytic modeling, treatment with oral linezolid during hospitalization and after discharge is expected to be the most cost-effective approach for treating SSIs caused by MRSA.
-
The safety and tolerability of duloxetine for major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and lower urinary tract disorders (LUTD) (including female stress urinary incontinence [SUI] and other LUTDs) has been established in individual clinical studies. The objective of this manuscript is to characterize the overall safety profile of duloxetine, regardless of indication, based on data from the duloxetine exposures integrated safety database. ⋯ The safety profile for the molecule from the overall duloxetine exposures integrated safety database suggests that benign and common pharmacologic side effects occur with duloxetine treatment. Because these pooled analyses do not allow for statistical comparison to placebo or active comparator, and include data from five different studied indications, these data do not suggest causality for AEs, nor are they necessarily generalizable to each disease stated studied.
-
Abdominal obesity, measured by waist circumference (WC), is a more accurate predictor of cardiometabolic risk than general obesity measured by body mass index (BMI). The 'Shape of the Nations' survey was performed to assess knowledge and understanding of the increased risk associated with abdominal obesity. ⋯ The Shape of the Nations survey findings demonstrate the need for education and action to improve preventive health efforts worldwide by educating PCPs, the general population and patients at risk about the dangers of abdominal obesity and of WC as an easy, reliable way to assess cardiometabolic risk.